| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7662365 | REDHILL | Polymer conjugates of opioid antagonists |
Oct, 2022
(11 months ago) | |
| US7786133 | REDHILL | Chemically modified small molecules |
Sep, 2028
(4 years from now) | |
| US9012469 | REDHILL | Crystalline naloxol-peg conjugate |
Apr, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617530 | REDHILL | Polymer conjugates of opioid antagonists |
Oct, 2022
(11 months ago) | |
| US7056500 | REDHILL | Polymer conjugates of opioid antagonists |
Jun, 2024
(8 months from now) | |
| US8067431 | REDHILL | Chemically modified small molecules |
Dec, 2024
(1 year, 2 months from now) | |
Movantik is owned by Redhill.
Movantik contains Naloxegol Oxalate.
Movantik has a total of 6 drug patents out of which 2 drug patents have expired.
Expired drug patents of Movantik are:
- US8617530
- US7662365
Movantik was authorised for market use on 16 September, 2014.
Movantik is available in tablet;oral dosage forms.
Movantik can be used as treatment of opioid-induced constipation.
The generics of Movantik are possible to be released after 02 April, 2032.
Drugs and Companies using NALOXEGOL OXALATE ingredient
Market Authorisation Date: 16 September, 2014
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
MOVANTIK family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic